Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$43.53-1.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · SUPN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||
| Revenues | 830.4 | 719.0 | 661.8 | 607.5 | 667.2 | 579.8 | 520.4 | 392.8 | 408.9 | 302.2 | 215.0 | 147.5 | 92.7 | 12.0 | 1.5 |
| Total Revenues | — | — | — | — | — | — | — | 392.8 | 408.9 | 302.2 | 215.0 | 147.5 | 92.7 | 12.0 | 1.5 |
| Cost of Revenues | 99.0 | 74.6 | 77.9 | 83.8 | 87.2 | — | 52.5 | 16.7 | 15.4 | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||||
| Selling, General & Admin | 560.9 | 485.6 | 321.6 | 336.4 | 377.2 | 304.8 | 200.7 | 153.2 | 154.7 | 137.9 | 106.0 | 89.1 | 72.6 | 55.6 | 20.1 |
| R&D Expenses | 126.1 | 106.2 | 108.8 | 91.6 | 74.6 | 90.5 | 76.0 | 69.1 | 89.2 | 49.6 | 42.8 | 29.1 | 19.6 | 17.2 | 23.5 |
| Operating Income | (130.5) | (62.3) | 81.7 | (5.3) | 46.1 | 86.0 | 173.7 | 148.6 | 144.4 | 99.5 | 54.2 | 20.8 | (5.3) | (61.9) | (42.2) |
| Earnings from Continuing Operations | |||||||||||||||
| Interest Expense | — | — | — | — | — | 19.7 | 19.4 | 18.2 | 13.8 | 0.1 | 0.5 | 1.2 | 5.0 | 7.8 | 3.6 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | 13.8 | 2.9 | 1.5 | 0.7 | 0.3 | 0.3 | 0.1 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | (0.0) | (2.7) | (0.9) | 0.5 | 4.6 | 7.6 | 3.5 |
| Other Non-Operating Income / Expenses | 7.0 | 13.3 | 16.2 | 8.0 | 14.6 | — | — | — | (4.3) | 1.1 | (3.8) | (6.2) | (5.0) | (30.4) | (4.1) |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — |
| EBT, Incl. Unusual Items | (123.5) | (49.0) | 97.9 | 2.8 | 60.7 | 73.2 | 168.6 | 147.5 | 140.2 | 100.6 | 50.4 | 14.6 | — | (92.3) | (46.3) |
| Income Tax Expense | (13.6) | (10.5) | 24.0 | 1.5 | 0.0 | 19.8 | 41.7 | 34.4 | 29.2 | 43.3 | (40.9) | 0.7 | — | 0.0 | 0.0 |
| Net Income | |||||||||||||||
| Net Income | (109.9) | (38.6) | 73.9 | 1.3 | 60.7 | 53.4 | 127.0 | 113.1 | 111.0 | 57.3 | 91.2 | 13.9 | (10.9) | (92.3) | (46.3) |
| Per Share | |||||||||||||||
| Basic EPS | (1.89) | (0.68) | 1.34 | 0.02 | 1.13 | 1.01 | 2.41 | 2.16 | 2.13 | 1.13 | 1.84 | 0.29 | (0.26) | — | — |
| Diluted EPS | (1.89) | (0.68) | 1.32 | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 | 2.05 | 1.08 | 1.76 | 0.28 | (0.26) | — | — |
| Revenue per Share | 14.30 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 58.1 | 56.5 | 55.1 | 54.5 | 53.7 | 53.1 | 52.6 | 52.4 | 52.0 | 50.8 | 49.5 | 47.5 | 42.3 | — | 17.4 |
| Diluted Weighted Avg Shares | 58.1 | 56.5 | 56.0 | 55.5 | 61.7 | 54.4 | 53.7 | 53.8 | 54.1 | 53.3 | 51.7 | 51.2 | 42.3 | — | 17.4 |
| Supplemental | |||||||||||||||
| EBITDA | — | (60.2) | 84.1 | (2.8) | 49.1 | 88.6 | 178.0 | 150.1 | 146.3 | 100.7 | 55.3 | 21.5 | (4.4) | (61.2) | (41.3) |
| EBIT | (130.5) | (62.3) | 81.7 | (5.3) | 46.1 | 86.0 | 173.7 | 148.6 | 144.4 | 99.5 | 54.2 | 20.8 | (5.3) | (61.9) | (42.2) |
| Effective Tax Rate | 11.0% | — | — | 52.5% | 0.1% | 27.0% | 24.7% | 23.3% | 20.8% | 43.1% | -81.1% | 4.6% | — | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.